Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
The CTMX news page on Stock Titan aggregates recent coverage and official announcements related to CytomX Therapeutics, Inc., a clinical-stage, oncology-focused biopharmaceutical company listed on the Nasdaq Global Select Market. CytomX reports that it is developing novel, conditionally activated, masked biologics based on its PROBODY® therapeutic platform, with a focus on cancer indications such as advanced colorectal cancer and advanced melanoma.
Visitors to this page can review news items that describe the progress of CytomX’s clinical programs, including updates on varsetatug masetecan (Varseta-M, formerly CX-2051), a masked EpCAM-directed antibody-drug conjugate with a topoisomerase-1 inhibitor payload, and CX-801, a masked interferon alpha-2b PROBODY® cytokine. Company press releases have discussed Phase 1 dose escalation and expansion activities, translational biomarker data, and plans for potential later-stage development in colorectal cancer and melanoma.
In addition to pipeline updates, CytomX news often includes financial results, business updates, and information about investor conference presentations. These items provide context on the company’s operating priorities, cash position, and interactions with the investment community. News releases also highlight research and collaboration activities involving its PROBODY® platform, such as work on T-cell engagers and cytokine-based approaches in partnership with other biopharmaceutical companies.
By following CTMX news, investors and researchers can monitor how CytomX describes the evolution of its PROBODY® technology, its clinical data disclosures, and its collaborations with partners including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. This page offers a centralized view of publicly released information that may be relevant to understanding the company’s development-stage oncology pipeline and corporate activities.
CytomX Therapeutics (CTMX) announced preliminary Phase 2 results for CX-2029, an antibody-drug conjugate targeting advanced squamous non-small cell lung cancer (sqNSCLC) and head and neck squamous cell carcinoma (HNSCC). In sqNSCLC, the objective response rate (ORR) was 18.8%, with a disease control rate (DCR) of 87.5%. HNSCC patients showed an ORR of 4.0% and a DCR of 56.0%. No new safety signals were detected, maintaining a favorable adverse event profile. The company continues to enroll patients and is optimistic about future data releases.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) announced that CEO Sean McCarthy will participate in virtual fireside chats at two investor conferences in November 2021. The Jefferies Global Healthcare Conference is scheduled for November 18, with the chat available online at 3:00 a.m. ET. The Piper Sandler Virtual Healthcare Conference will follow on November 30, with the chat accessible at 10:00 a.m. ET. Archived replays will be available on the company's website for 30 days. CytomX is pioneering conditionally activated therapeutics focusing on oncology.
CytomX Therapeutics (CTMX) reported its third quarter 2021 financial results, showcasing a revenue of $18 million, consistent with 2020 figures. The company is on track to release initial data from the Phase 2 studies of CX-2029 in Q4 2021 and praluzatamab ravtansine (CX-2009) in 2022. R&D expenses increased to $29 million due to clinical trials and related costs. The company maintains a strong cash position of $336 million. Additionally, CX-904's IND filing is anticipated in late 2021, emphasizing CytomX’s commitment to advancing its conditionally activated therapeutics.
CytomX Therapeutics (CTMX) announced the presentation of preclinical data on a conditionally activated interferon alpha-2b at the SITC 2021 Annual Meeting from November 12-14, 2021. The data highlights the safety and anti-cancer activity of this treatment, showcasing the potential of CytomX's Probody® technology platform. This innovative approach aims to minimize toxicity while enhancing therapeutic efficacy against cancer. With a robust clinical pipeline, CytomX is focused on developing safer, more effective therapies for patients.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) announced their upcoming third quarter 2021 financial results on November 4, 2021, following U.S. market closure. A conference call at 5:00 p.m. ET will provide insights into the results and corporate updates. CytomX is focused on developing conditionally activated therapeutics via their Probody® technology platform, aiming to improve cancer therapy effectiveness while minimizing toxicity. The company collaborates with industry leaders like AbbVie and Bristol Myers Squibb, having a pipeline with multiple assets in Phase 2 clinical trials.
CytomX Therapeutics (Nasdaq: CTMX), a biopharmaceutical company focused on oncology, announced the grant of stock options to six new employees on October 15, 2021. A total of 177,000 shares were offered at an exercise price of $5.14, matching the closing price on the grant date. The options are part of the 2019 Employment Inducement Incentive Plan, approved by the board in August 2020. CytomX specializes in conditionally activated therapeutics, employing its Probody® technology platform, to target cancer with minimized toxicity.
CytomX Therapeutics (Nasdaq: CTMX) has appointed Alan Ashworth, Ph.D., a distinguished cancer researcher, to its board of directors. Dr. Ashworth, known for identifying the BRCA2 gene and developing PARP inhibitors, brings extensive experience to advance CytomX's clinical pipeline. President Sean McCarthy emphasized Dr. Ashworth's expertise in translational sciences will be valuable as the company targets key Phase 2 milestones. CytomX focuses on conditionally activated therapeutics using its Probody technology to improve cancer treatment outcomes while minimizing toxicity.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) announced the granting of stock options to nine new employees, totaling 157,200 shares at an exercise price of $4.97, matching the closing price on September 15, 2021. These options were issued under the 2019 Employment Inducement Incentive Plan to attract new talent. CytomX is focused on developing conditionally activated therapeutics for cancer treatment based on its Probody technology, with significant collaborations with major firms like AbbVie and Bristol Myers Squibb, and a portfolio featuring multiple candidates in clinical trials.
CytomX Therapeutics (Nasdaq: CTMX) announced that Sean McCarthy, D.Phil., will participate in a virtual fireside chat during the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.
The pre-recorded session will be available for on-demand viewing starting September 13 at 7:00 a.m. ET on CytomX’s website, with a 90-day archive afterwards. CytomX is developing Probody therapeutics aimed at treating cancer, focusing on minimizing toxicity while enhancing treatment efficacy.
CytomX Therapeutics (CTMX) announced the grant of stock options to seven new employees for a total of 172,600 shares at $4.81 each, reflecting the closing price on August 16, 2021. This grant, made under the 2019 Employment Inducement Incentive Plan, aims to attract new talent. CytomX, an oncology-focused biopharmaceutical firm, specializes in conditionally activated antibody therapeutics using its Probody® technology platform to target cancer effectively while minimizing toxicity. The company collaborates with major pharmaceutical partners and has a clinical pipeline advancing towards Phase 2 studies.